Ariad Pharmaceuticals Inc fka ARIA

[AmpleKind]

From biomaven:

Iclusig, albeit the most powerful drug, does not cure CML - patients have to keep taking it as long as they live. So an unacceptable SAE rate would make that impractical.

That is a well know fact! I don't think it modifies in any way Peter's previous and
somewhat more optimistic sounding assessment.

Unless SAE's can be mitigated, the drug is for patients
who would die without it. That sub-population is well defined and one might add,
a growing population at that. What constitutes "an unacceptable SAE rate" depends
on the nature and stage of the disease for a given patient. When you have weeks or
months to live, a drug that gives you immediate relief, but with a (let's say) a 5% chance
of an SAE in the first year, Iclusig is a very desirable alternative.